PHARMACOSMOS
At Pharmacosmos, we are specialists in iron therapy. they develop, manufacture and market medicines for the treatment of iron deficiency anaemia in humans and animals. they are furthermore specialists in developing and producing advanced carbohydrates for pharmaceutical and technical uses.
PHARMACOSMOS
Industry:
Biotechnology Manufacturing
Address:
Denmark, South Carolina, United States
Country:
United States
Website Url:
http://www.pharmacosmos.com
Status:
Active
Contact:
+45 5948 5959
Email Addresses:
[email protected]
Technology used in webpage:
IPv6 3 To 9 CcTLD Redirects ASP.NET Core Kestrel About Cookies
Similar Organizations
National Science Foundation
America’s Seed Fund at the National Science Foundation awards nearly $200 million annually to startups and small businesses.
Vanrx Pharmasystems
Vanrx Pharmasystems manufactures aseptic filling machines that improve the production of sterile injectables.
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-11-11 | Abfero Pharmaceuticals | Abfero Pharmaceuticals acquired by Pharmacosmos | N/A |
Official Site Inspections
http://www.pharmacosmos.com Semrush global rank: 4.81 M Semrush visits lastest month: 1.89 K
- Host name: acd89244c803f7181.awsglobalaccelerator.com
- IP address: 75.2.60.5
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Pharmacosmos"
Pharmacosmos - Wikipedia
Pharmacosmos was founded in Denmark in 1965 by Henry Marinus Christensen, M.D., Ph.D. Pharmacosmos' corporate headquarters, manufacturing facilities and research laboratories are located in Holbaek, Denmark (Scandinavia). The company has its own marketing, sales and services operations in Denmark and US, UK, Ireland, Germany, Sweden, Norway and China. In other geographies, the company partners with other pharmaceutical companies responsible for local …See details»
Aspiration & Values - Pharmacosmos
At Pharmacosmos, we want to change the way iron deficiency is prevented and treated in humans and animals. We do so by striving to stay at the scientific forefront and by partnering with …See details»
Our defining moments - Pharmacosmos
Pharmacosmos was established in 1965 by Henry Christensen MD, PhD, who was succeeded by his youngest son Lars Christensen, MD, as CEO in 1993. The company has since its …See details»
Pharmacosmos - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +45 5948 5959 At Pharmacosmos, we are specialists in iron therapy. they develop, manufacture …See details»
Pharmacosmos - LinkedIn
Pharmacosmos is considered a world leading authority in treatment of iron deficiency anaemia. Headquartered in Denmark, Pharmacosmos is a family-owned, international healthcare company with more ...See details»
Pharmacosmos - Leadership Team - The Org
The Leadership Team at Pharmacosmos oversees the strategic direction and overall operations of the company. Comprising senior executives from various departments, including finance, …See details»
About Pharmacosmos
Pharmacosmos A/S is a family-held, fully integrated pharmaceutical company, located in Holbæk, Denmark. With the headquarter being in Denmark, the Nordic affiliate has a natural and close …See details»
Aspiration & Values - PHARMACOSMOS
Pharmacosmos Therapeutics shares the Pharmacosmos Group's aspirations and values Across the world, more than 1 billion people live with iron deficiency anemia, making it one of the largest global health challenges of our time 1. At …See details»
Pharmacosmos - The Org
At Pharmacosmos, they are specialists in iron therapy. Industries. Biotechnology, ManufacturingSee details»
Pharmacosmos - Management Team - The Org
The Management Team at Pharmacosmos is responsible for overseeing the strategic direction, financial health, and commercial success of the company. They ensure effective governance, …See details»
Pharmacosmos Therapeutics - Crunchbase Company Profile
Aug 7, 2024 Pharmacosmos Therapeutics Inc. is an affiliate of Pharmacosmos that sells Monoferric in the US high-dose IV iron market. Lists Featuring This Company. Edit Lists …See details»
Pharmacosmos - sabm.org
We are the U.S. affiliate of the Denmark-based Pharmacosmos Group. Please visit us at www.monoferric.com to learn more. Karina Utkina, PharmD Medical Director, Medical Affairs …See details»
Pharmacosmos Company Profile 2024: Valuation, Funding
Pharmacosmos General Information Description. Developer of medicines for the treatment of iron deficiency anaemia in humans and animals. The company is engaged in research and …See details»
Pharmacosmos - Marketing and Sales - The Org
The Marketing and Sales team at Pharmacosmos is responsible for strategizing and implementing plans to promote and sell their iron therapy products. This involves market analysis, managing …See details»
Pharmacosmos is booming: Has doubled in two years - MedWatch
Jun 30, 2023 Danish pharmaceutical company Pharmacosmos is undergoing a period of rapid growth, and in the latest financial year, 2022/23, the company that produces iron treatments …See details»
Working at Pharmacosmos
Pharmacosmos A/S is a family-held, fully integrated pharmaceutical company, located in Holbæk, Denmark. With the headquarter being in Denmark, the Nordic affiliate has a natural and close …See details»
Pharmacosmos - Overview, News & Similar companies - ZoomInfo
Menarini Asia-Pacific partners with Pharmacosmos to expand its reach of MonoFer® to Singapore and Malaysia SINGAPORE, June 19, 2024 /PRNewswire/ -- Menarini Asia-Pacific (Menarini) …See details»
Pharmacosmos - HR and Compliance - The Org
The HR and Compliance team at Pharmacosmos is responsible for ensuring that the company adheres to all regulatory requirements and internal policies related to human resources. They …See details»
Pharmacosmos picks up G1 Therapeutics, FDA-approved drug …
Aug 7, 2024 Pharmacosmos put in a cash offer for all outstanding shares of G1's common stock for $7.15 per share, and the deal is expected to close late in this year’s third quarter.See details»